Back | Next |
home / stock / btai / btai message board
Subject | By | Source | When |
---|---|---|---|
Looks pretty positive | lettruthringout | investorshub | 06/05/2023 10:53:21 PM |
$BTAI MomentumIts gaining | realfast95 | investorshub | 06/05/2023 2:08:13 AM |
news out | realfast95 | investorshub | 06/03/2023 6:20:31 AM |
Anyone hear anything lately? Want to see this one go | realfast95 | investorshub | 06/02/2023 3:11:00 AM |
short squeeze | realfast95 | investorshub | 06/01/2023 11:34:12 PM |
$BTAI The now last up | realfast95 | investorshub | 05/07/2023 5:01:52 PM |
The trading last trade up | realfast95 | investorshub | 05/07/2023 10:02:44 AM |
MomentumIts now | realfast95 | investorshub | 05/06/2023 8:29:08 AM |
$BTAI Price trading | realfast95 | investorshub | 05/04/2023 4:37:53 PM |
The trading | realfast95 | investorshub | 05/03/2023 5:36:26 AM |
$BTAI Thoughts on where this is headed? | MDizzle | investorshub | 05/02/2023 10:59:40 PM |
best news of the day | lettruthringout | investorshub | 05/01/2023 8:41:04 PM |
$BTAI Do we have a winner?Turn around time? | Penny chatter | investorshub | 05/01/2023 12:01:08 PM |
$BTAI Price trading last trade up | realfast95 | investorshub | 05/01/2023 4:29:52 AM |
$BTAI MomentumIts gaining up | realfast95 | investorshub | 05/01/2023 3:38:47 AM |
The gaining up | realfast95 | investorshub | 05/01/2023 1:52:17 AM |
$BTAI Time for this to show some returns | realfast95 | investorshub | 04/30/2023 6:46:42 PM |
bears and bulls | realfast95 | investorshub | 04/29/2023 11:42:00 AM |
$BTAI great article | lettruthringout | investorshub | 04/28/2023 7:31:43 PM |
$BTAI MomentumIts now | realfast95 | investorshub | 04/28/2023 3:39:42 PM |
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Advancing TRANQUILITY and SERENITY program plans for two pivotal Phase 3 trials to expand BXCL501 market potential in acute treatment of agitation Strengthened intellectual property portfolio for BXCL501 with grant of two new patents, in Japan and the U.S. Completed $25 million re...